Trial · NCT00348686
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
NCT00348686, Phase 4, Completed, AstraZeneca; results first posted 2012-04-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP). Trials, record NCT00348686. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00348686
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
- NCT number
- NCT00348686
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 315 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Hypertension, Left Ventricular Hypertrophy
- Interventions
- Candesartan, Candesartan, Felodipine, Felodipine
- First posted
- 2006-07-06
- Last updated
- 2012-04-02
- Results first posted
- 2012-04-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change of B Type Natriuretic Peptides (BNP) Level | At Baseline and 24 weeks | Change of B Type Natriuretic Peptides Level of the Subjects With Hypertension and Left Ventricular Hypertrophy (LVH) Treated With Candesartan Based Therapy for 24 Weeks was calculated just as the later time point minus the earlier time point. No specific calculation was used. |
| Secondary | LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index | At Baseline and 24 weeks | Change of Left Ventricular Hypertrophy(LVH) by Echocardiac Parameter, Left Ventricular mass Index (LVMI) was calculated and collected through the way of Last Observational carried forward. LVH/Index was calculated like this: Divide LV mass with Body Surface Area. |
| Secondary | Change of Systolic Blood Pressure (SBP) | At Baseline and 24 weeks | Change of Systolic Blood Pressure was calculated and collected through the way of Last Observational carried forward. |
| Secondary | Change of Diastolic Blood Pressure (DBP) | At Baseline and 24 weeks | Change of Diastolic Blood Pressure was calculated and collected through the way of Last Observational carried forward. Only who has diastolic blood pressure data both baseline and follow up was analyzed. Most of patient who enrolled, 302 have a data. |
| Secondary | Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only | At Baseline and 24 weeks | Percent change of proBNP(B type Natriuretic Peptides) was calculated and collected through the way of Last Observational carried forward. |
| Secondary | Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine | At Baseline and 24 weeks | Percent change of proBNP(B type Natriuretic Peptides) was calculated and collected through the way of Last Observational carried forward. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change of B Type Natriuretic Peptides (BNP) Level | At Baseline and 24 weeks | Followed Intent-to-treat analysis | Percent Change | MEDIAN |
| SECONDARY | LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index | At Baseline and 24 weeks | Only 245 patients who have reliable Echocardiac data were analyzed. | g/m^2 | MEDIAN |
| SECONDARY | Change of Systolic Blood Pressure (SBP) | At Baseline and 24 weeks | Only who has systolic blood pressure data both baseline and follow up was analyzed. Most of patient who enrolled, 302 have a data. | mmHg | MEDIAN |
| SECONDARY | Change of Diastolic Blood Pressure (DBP) | At Baseline and 24 weeks | Last Observational carried forward | mmHg | MEDIAN |
| SECONDARY | Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only | At Baseline and 24 weeks | Only 201 patients are available for analysis. | percent change | MEDIAN |
| SECONDARY | Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine | At Baseline and 24 weeks | Only 91 patients are available for analysis | percent change | MEDIAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change of B Type Natriuretic Peptides (BNP) Level | Candesartan | -29.2 | Full Range -35.3 to -16.7 | Percent Change | |
| LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index | Candesartan | -10.90 | Full Range -14.00 to -7.0 | g/m^2 | |
| Change of Systolic Blood Pressure (SBP) | Candesartan | -32.0 | Full Range -35.0 to -30.0 | mmHg | |
| Change of Diastolic Blood Pressure (DBP) | Candesartan | -20.0 | Full Range -20.0 to -18.0 | mmHg | |
| Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only | Candesartan | -18.9 | Full Range -33.0 to -6.6 | percent change | |
| Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine | Candesartan | -36.1 | Full Range -57.9 to -24.3 | percent change |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Candesartan | 315 | |
| Overall Study | COMPLETED | Candesartan | 249 | |
| Overall Study | NOT COMPLETED | Candesartan | 66 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Candesartan | 23 | 315 | |
| other | Dizziness | Nervous system disorders | Candesartan | 16 | 315 | |
| serious | Left paraduodenal hernia | Gastrointestinal disorders | Candesartan | 1 | 315 | |
| serious | Rectal prolapse aggravated | Gastrointestinal disorders | Candesartan | 1 | 315 | |
| serious | Cerebral infarction | Vascular disorders | Candesartan | 1 | 315 | |
| serious | Uterine myoma aggravated | Renal and urinary disorders | Candesartan | 1 | 315 | |
| serious | Cervical disc herniation aggravated | General disorders | Candesartan | 1 | 315 | |
| serious | Pneumonia with effusion in the right chest | Respiratory, thoracic and mediastinal disorders | Candesartan | 1 | 315 | |
| serious | Granuloma inguinale | Skin and subcutaneous tissue disorders | Candesartan | 1 | 315 | |
| serious | Acute myocardial infarction | Cardiac disorders | Candesartan | 1 | 315 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Candesartan | ||
| Total, other adverse events | Candesartan | 37 | |
| Total, serious adverse events | Candesartan | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00348686
GET https://conductscience.org/api/trials/v1/NCT00348686/registered